264 related articles for article (PubMed ID: 18563057)
21. Pharmacoeconomics and health policy. Current applications and prospects for the future.
Greenberg PE; Arcelus A; Birnbaum HG; Cremieux PY; LeLorier J; Ouellette P; Slavin MB
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):425-32. PubMed ID: 10662390
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoeconomics--an aid to better decision-making.
Arenas-Guzman R; Tosti A; Hay R; Haneke E;
J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
[TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
24. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
[TBL] [Abstract][Full Text] [Related]
25. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
Henry D
Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
[TBL] [Abstract][Full Text] [Related]
26. Comparative experience in home care and pharmaceutical policy.
Kane NM; Saltman RB
Health Policy; 1997 Sep; 41 Suppl():S1-7. PubMed ID: 10174467
[No Abstract] [Full Text] [Related]
27. Rising drug prices drive US manufacturers' revenues, analysis finds.
McCarthy M
BMJ; 2015 Oct; 351():h5376. PubMed ID: 26446098
[No Abstract] [Full Text] [Related]
28. Economics, pharmaceuticals, and pharmacoeconomics.
Johannesson M; O'Brien BJ
Med Decis Making; 1998; 18(2 Suppl):S1-3. PubMed ID: 9566460
[No Abstract] [Full Text] [Related]
29. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
[TBL] [Abstract][Full Text] [Related]
30. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
31. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.
Bodrogi J; Kaló Z
Br J Pharmacol; 2010 Apr; 159(7):1367-73. PubMed ID: 20132213
[TBL] [Abstract][Full Text] [Related]
32. The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report.
Draugalis JR; Coons SJ
Clin Ther; 1994; 16(3):523-37; discussion 522. PubMed ID: 7923318
[TBL] [Abstract][Full Text] [Related]
33. Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research.
Minshall ME; Kody MC; Mosbacher F
Med Care; 1999 Apr; 37(4 Suppl Lilly):AS12-9. PubMed ID: 10217388
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacoeconomics in contemporary medicine].
Czech M
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
[TBL] [Abstract][Full Text] [Related]
35. Pharmacoeconomics and managed care: methodologic and policy issues.
Luce BR
Med Decis Making; 1998; 18(2 Suppl):S4-11. PubMed ID: 9566461
[No Abstract] [Full Text] [Related]
36. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
[TBL] [Abstract][Full Text] [Related]
37. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.
Thwaites R; Townsend RJ
Pharmacoeconomics; 1998 Feb; 13(2):175-80. PubMed ID: 10178645
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomics: an emerging discipline.
Letizia C
Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
[TBL] [Abstract][Full Text] [Related]
39. Cost of Cancer Drugs: Something Has To Give.
Bender E
Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
[TBL] [Abstract][Full Text] [Related]
40. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
Vandergrift M; Kanavos P
Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
